Navigation Links
Abbott Hosts Conference Call for Third-Quarter Earnings
Date:9/19/2008

ABBOTT PARK, Ill., Sept. 19 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) will announce its 2008 third-quarter financial results on Wednesday, Oct. 15, 2008, before the market opens.

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations Web site at http://www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Abbott to Present at UBS Best of Americas Investment Conference
2. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
3. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
4. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
5. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
6. Abbott Invests Additional $20M in Isis Subsidiary Ibis Biosciences
7. Abbott to Present at Goldman Sachs Global Healthcare Conference
8. Abbott Launches Next-Generation StarClose(R) SE Vascular Closure System
9. Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder
10. Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline
11. Abbott Announces Labs Are Vital(TM) Facebook Scholarship Contest Winners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2015)... ... 26, 2015 , ... Maine Standards Company, LLC is pleased ... kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and Vitamin B12 in a ... recommended “equal delta” method for linearity testing and is liquid, ready-to-use. Simply add ...
(Date:7/24/2015)... 2015 Ryan & Maniskas, LLP that ... District Court for the Northern District of California ... purchased the common stock of Avalanche Biotechnologies, Inc. ("Avalanche" or ... and June 15, 2015, inclusive (the "Class Period"). ... the Court for appointment as a lead plaintiff of the ...
(Date:7/24/2015)... , July 24, 2015 ... equities: PDL BioPharma Inc. (NASDAQ: PDLI ), Arena ... STEM ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ... Free research report on PDL BioPharma can be accessed ... the NASDAQ Composite ended at 5,146.41, down 0.49%, the ...
(Date:7/24/2015)... , July 24, 2015 Orexigen Therapeutics, ... financial results for the second quarter 2015 on Thursday, ... Orexigen will provide a business update and discuss the ... at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... phone by calling (800) 447-0521 (domestic) or (847) 413-3238 ...
Breaking Biology Technology:Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... financial numbers for the end of fiscal 2005 on Thursday, ... ,Revenues were $8.3 million, an 89 percent increase over the ... to multiple unit sales, repeat purchases, new product offerings and ... however, and the company posted a loss of $4.2 million, ...
... Wisconsin in the next ten years, according to a proposal ... reach the Senate for a vote this month. State Senator ... in Wisconsin that would be regulated similarly to airports. , ... to regulate private space travel in the area, receive any ...
... investors in early-stage companies has shown results in its first ... so far applied for $1.8 million of the $3 million ... figures show. But of the $3.5 million in tax credits ... ,"We knew there would be a lag on the venture ...
Cached Biology Technology:Space port could open in Sheboygan in next 10 years 2Space port could open in Sheboygan in next 10 years 3Act 255 heats up angel investment in 2005, though VC involvement lags 2Act 255 heats up angel investment in 2005, though VC involvement lags 3
(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Providing food security, one of the greatest challenges ... the developing world, where crop destruction by drought, disease ... risk of hunger. Scientists at the University of ... on cowpea, a protein-rich legume crop of immense importance ...
... NJ Uncover the neural communication links involved in ... it may become possible to reverse the breakdown of ... multiple sclerosis, spinal cord injuries, diabetes and cancers of ... the New Jersey Commission on Spinal Cord Injury and ...
... 14 satellites currently in orbit and the National Aeronautics ... been able to observe the Earths environment to help ... The use of remote sensing technology aids specialists ... common and deadly infectious diseases today such as Ebola, ...
Cached Biology News:UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 2UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 3UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 4Rutgers scientist's research reveals critical knowledge about the nervous system 2NASA technology helps predict and prevent future pandemic outbreaks 2